Scholar Rock Holding Corporation (SRRK) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, MA, United States. Le PDG actuel est David L. Hallal.
SRRK a date d'introduction en bourse 2018-05-25, 128 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $5.67B.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering and developing medicines that target protein growth factor signaling pathways to treat serious diseases. The company's lead candidate, Apitegromab, a myostatin activation inhibitor, has completed Phase 3 clinical trials for spinal muscular atrophy treatment, while SRK-181 is in Phase 1 development for checkpoint inhibitor-resistant cancers. Scholar Rock maintains a strategic collaboration with Gilead Sciences to develop transforming growth factor beta inhibitors for fibrotic diseases, with a broader pipeline addressing neuromuscular disorders, oncology, and fibrosis indications. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company aims to transform patient outcomes across multiple serious disease areas through its targeted therapeutic approach.
